KumarRSmithREHenryBL. A review and recommendations for the management of patients with life-threatening dabigatran associated hemorrhage: a single-center university hospital experience [published online March 14, 2014]. J Intensive Care Med. 2014.
2.
van RynJStangierJHaertterS. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127.
3.
GlundSStangierJSchmohlM. A specific antidote for dabigatran: immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy male volunteers. Circulation. 2013;128(22 suppl):Abstr 17765. Presented at the 86th Scientific Sessions of the American Heart Association; November 18, 2013; Dallas, TX.
4.
SchieleFvan RynJCanadaK. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–3562.
5.
GrottkeOVan RynJRossaintR. In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran. Crit Care. 2014;18(suppl 1):P118. doi:10.1186/cc13308.
